与癌共舞

  • 患者服务: 与癌共舞小助手
  • 微信号: xzs60619

QQ登录

只需一步,快速开始

开启左侧

EGFR和ALK同时突变的肺癌回顾性分析

[复制链接]
4124 3 costa_na 发表于 2014-1-25 21:11:36 |

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有帐号?注册

x
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation

Yang J, Zhang XC, Su J, Xu C, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY, Wang Z, Wang BC, Yang X, Zhong W, Nie Q, Liao RQ, Mok TS, Wu YL.

Abstract

PURPOSE:
We investigated the incidence of concomitant EGFR mutations and ALK rearrangements in Chinese patients with non-small-cell lung cancer (NSCLC), and assessed responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and crizotinib in such tumors.

EXPERIMENTAL DESIGN:
We screened 977 consecutive patients with NSCLC for the presence of concomitant EGFR mutations and ALK rearrangements by rapid amplification of cDNA ends-coupled polymerase chain reaction sequencing and fluorescence in situ hybridization. Immunohistochemistry (IHC) and Western blotting were used to correlate the activation of EGFR, ALK and downstream proteins with responses to EGFR-TKIs and crizotinib.

RESULTS:
The overall frequency of concomitant EGFR mutations and ALK rearrangements was 1.3% (13/977). EGFR/ALK co-alterations were found in 3.9% (13/336) EGFR-mutant and 18.6% (13/70) ALK-rearranged patients. Ten tumors were treated with first-line EGFR-TKIs, with a response rate of 80% (8/10). Two tumors with high phospho-ALK levels and low phospho-EGFR levels achieved stable and progressive disease, respectively. Median progression-free survival was 11.2 months. Co-expression of mutant EGFR and ALK fusion proteins in the same tumor cell populations was detected by IHC. Two cases with high phospho-ALK levels treated with crizotinib achieved partial responses; two cases with low phospho-ALK levels had progressive or stable disease.

CONCLUSION:
ALK rearrangements and EGFR mutations could co-exist in a small subgroup of NSCLC. Advanced pulmonary adenocarcinomas with such co-alterations could have diverse responses to EGFR-TKIs and crizotinib. Relative phospho-ALK and phospho-EGFR levels could predict the efficacy of EGFR-TKI and crizotinib.

http://www.ncbi.nlm.nih.gov/pubmed/24443522

中国非小细胞肺癌患者中,EGFR突变率为336/977 (34.4%),ALK重排率为70/977 (7.2%),二者皆有的患者占13/977 (1.3%)。80%对EGFR-TKI治疗有反应,且与EGFR、ALK改变的程度有关。

3条精彩回复,最后回复于 2018-9-28 06:55

seacat  版主 发表于 2014-1-26 00:41:08 | 显示全部楼层
一切皆有可能,惟有以身试药了
elexujx  大学一年级 发表于 2014-3-1 09:54:43 | 显示全部楼层
有点没看明白. 请教Costa: EGFR/ALK co-alterations 就是  concomitant EGFR mutations and ALK rearrangements? Ten tumors 是指 Ten patients?

发表回复

高级模式
B Color Image Link Quote Code Smilies

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
改版要求
扫一扫,关注论坛微信
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表